Skip to main content
Top
Published in: AIDS and Behavior 2/2013

01-02-2013 | Original Paper

Feasibility, Performance, and Acceptability of the Wisebag™ for Potential Monitoring of Daily Gel Applicator Use in Durban, South Africa

Authors: Ariane van der Straten, Elizabeth Montgomery, Diantha Pillay, Helen Cheng, Anushka Naidoo, Zakhele Cele, Kalendri Naidoo, Miriam Hartmann, Jeanna Piper, Gonasagrie Nair

Published in: AIDS and Behavior | Issue 2/2013

Login to get access

Abstract

The Wisebag™, a lunchbag-style container with an electronic events-monitoring system, was designed as a real-time indirect objective measure of microbicide gel use. Due to cost, alternative functionalities (i.e. use of offline and dummy versions) were explored. We conducted a three-arm, double-blinded pilot study among 50 HIV-negative women in Durban, South Africa to assess participant adherence and Wisebag acceptability and performance. Participants were randomized 2:2:1 to Wisebag with online (events transmitted via cellular signal in real-time), offline (events stored in device memory) or inactive “dummy” devices. Participants were instructed to open the Wisebag daily for 2 weeks, retrieve a study sticker and affix it on a diary card. All participants completed the study. At exit, 94 % did not know which device they had received, nor could they differentiate the Wisebag types when presented with the three options. Five offline devices failed (no data recorded). Per Wisebag events, 26 % of women were perfectly adherent compared to 48 % by self-report and 46 % per diary card. Of reported non-adherence, 92 % did not open the Wisebag (travelling or forgot) and 22 % opened Wisebag >1×/day (curiosity). Participants liked and were comfortable carrying Wisebag. Successful blinding will allow inclusion of offline and/or dummy Wisebags in future study designs. Perfect adherence by opening events was significantly lower than by self-report, highlighting the importance of objective measures of adherence in clinical trials. Additional studies to validate Wisebag data with actual products, with and without SMS and online functionality, in different populations and settings, and in comparison to biomarkers are warranted.
Literature
1.
go back to reference Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.
2.
go back to reference Weiss H, Wasserheit J, Barnabas R, Hayes R, Abu-Raddad L. Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol. 2008;5(1):8.PubMedCrossRef Weiss H, Wasserheit J, Barnabas R, Hayes R, Abu-Raddad L. Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol. 2008;5(1):8.PubMedCrossRef
3.
go back to reference Hendrix C, Minnis A, Guddera V, et al., editors. MTN-001: a phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations. 18th conference on retroviruses and opportunistic infections. Boston; 2011. Hendrix C, Minnis A, Guddera V, et al., editors. MTN-001: a phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations. 18th conference on retroviruses and opportunistic infections. Boston; 2011.
4.
go back to reference Mâsse BR, Boily MC, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol. 2009;6(1):5.PubMedCrossRef Mâsse BR, Boily MC, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol. 2009;6(1):5.PubMedCrossRef
5.
go back to reference van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of PrEP trials for HIV prevention. AIDS. 2012;26(7):F13–9.PubMedCrossRef van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of PrEP trials for HIV prevention. AIDS. 2012;26(7):F13–9.PubMedCrossRef
6.
go back to reference Tolley EE, Harrison PF, Goetghebeur E, et al. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav. 2010;14(5):1124–36.PubMedCrossRef Tolley EE, Harrison PF, Goetghebeur E, et al. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav. 2010;14(5):1124–36.PubMedCrossRef
7.
go back to reference Wallace A, Teitelbaum A, Wan L, Mulima M, Guichard L. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76(1):53–6.PubMedCrossRef Wallace A, Teitelbaum A, Wan L, Mulima M, Guichard L. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76(1):53–6.PubMedCrossRef
8.
go back to reference Katzen LL, Fernández-Romero JA, Sarna A, et al. Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Sex Transm Dis. 2011;38(11):1050.PubMedCrossRef Katzen LL, Fernández-Romero JA, Sarna A, et al. Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Sex Transm Dis. 2011;38(11):1050.PubMedCrossRef
9.
go back to reference Moench TR, O’Hanlon DE, Cone RA. Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis. 2012; Published Ahead-of-Print. Moench TR, O’Hanlon DE, Cone RA. Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis. 2012; Published Ahead-of-Print.
10.
go back to reference Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378(9787):279–81.PubMedCrossRef Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378(9787):279–81.PubMedCrossRef
11.
go back to reference Berg K, Arnsten J. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79.PubMedCrossRef Berg K, Arnsten J. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79.PubMedCrossRef
12.
go back to reference Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012.
13.
go back to reference Gengiah T, Mansoor L, Naidoo A, et al., editors. The CAPRISA 004 ‘Wisebag’: enhancing adherence measurement in microbicide trials. microbicides 2010 conference. Pittsburgh; 2010. Gengiah T, Mansoor L, Naidoo A, et al., editors. The CAPRISA 004 ‘Wisebag’: enhancing adherence measurement in microbicide trials. microbicides 2010 conference. Pittsburgh; 2010.
14.
go back to reference Haberer J, Kahane J, Kigozi I, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340–6.PubMedCrossRef Haberer J, Kahane J, Kigozi I, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340–6.PubMedCrossRef
15.
go back to reference Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968–77.PubMed Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968–77.PubMed
16.
go back to reference Haberer J, Psaros C, Baeten J, et al. High adherence to oral PrEP is associated with lack of infections in an ancillary study of objective adherence monitoring and counseling among HIV discordant couples in Partners PrEP Study. 19th conference on retroviruses and opportunistic infections; 2012 March 5–8; Seattle. Haberer J, Psaros C, Baeten J, et al. High adherence to oral PrEP is associated with lack of infections in an ancillary study of objective adherence monitoring and counseling among HIV discordant couples in Partners PrEP Study. 19th conference on retroviruses and opportunistic infections; 2012 March 5–8; Seattle.
Metadata
Title
Feasibility, Performance, and Acceptability of the Wisebag™ for Potential Monitoring of Daily Gel Applicator Use in Durban, South Africa
Authors
Ariane van der Straten
Elizabeth Montgomery
Diantha Pillay
Helen Cheng
Anushka Naidoo
Zakhele Cele
Kalendri Naidoo
Miriam Hartmann
Jeanna Piper
Gonasagrie Nair
Publication date
01-02-2013
Publisher
Springer US
Published in
AIDS and Behavior / Issue 2/2013
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-012-0330-y

Other articles of this Issue 2/2013

AIDS and Behavior 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.